MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer

Journal of Hepatology

Volumn 63, Issue 2, 2015, Pages 408-419

  Bae, Hyun Jin ^a   Jung, Kwang Hwa ^a   Eun, Jung Woo ^a   Shen, Qingyu ^a   Kim, Hyung Seok ^a   Park, Se Jin ^a   Shin, Woo Chan ^a   Yang, Hee Doo ^a   Park, Won Sang ^a   Lee, Jung Young ^a   Nam, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Histone deacetylase 6; JNK c Jun; Liver cancer; MicroRNA 221; NF B

Indexed keywords

ALPHA TUBULIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BECLIN 1; DICER; HISTONE DEACETYLASE 6; MICRORNA 22; MICRORNA 221; MICRORNA 222; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; HDAC6 PROTEIN, MOUSE; HISTONE DEACETYLASE; MICRORNA; MIRN221 MICRORNA, MOUSE; RNA;

ARTICLE; CANCER GROWTH; CELL VIABILITY; CELLS; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME INACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LIVER; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION; TRANSCRIPTION INITIATION; ANIMAL; BIOSYNTHESIS; DISEASE COURSE; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; POLYMERASE CHAIN REACTION; RAT; TRANSGENIC MOUSE;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MICRORNAS; POLYMERASE CHAIN REACTION; RATS; RNA, NEOPLASM;

EID: 84942819746     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.03.019     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J. Ward E and Forman D Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
3. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9:206-218.
4. Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol 2011;2011:371832.
5. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003;983:84-100.
6. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Chang YG, et al. Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinasemediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 2012;56:644-657.
7. Kim JK, Noh JH, Eun JW, Jung KH, Bae HJ, Shen Q, et al. Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer. Mol Cancer Res 2013;11:62-73.
8. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013;57:1055-1067.
9. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 2010;29:969-980.
10. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-458.
11. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 2008;68:7561-7569.
12. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005;24:4531-4539.
13. MicroRNAs Bartel DP. Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
14. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
15. Meng F, Henson R, Wehbe-Janek H, Ghoshal K. Jacob ST and Patel T MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-658.
16. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, et al. Effects of microRNA- 29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010;51:836-845.
17. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR- 221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010;107:264-269.
18. Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog 2013. http://dx.doi.org/10.1002/mc.22122.
19. Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel AL, et al. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res 2012;318:1832-1843.
20. Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, et al. MicroRNA- 221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 2013;57:299-310.
21. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR- 221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509.
22. Galardi S, Mercatelli N, Farace MG, Ciafre SA. NF-κB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res 2011;39:3892-3902.
23. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005;4:1577-1584.
24. Li J, Lau G, Chen L, Yuan YF, Huang J, Luk JM, et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One 2012;7:e46264.
25. Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 2008;283:21065-21073.
26. Ding G, Liu HD, Huang Q, Liang HX, Ding ZH, Liao ZJ, et al. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity. FEBS Lett 2013;587:880-886.
27. Kanno K, Kanno S, Nitta H, Uesugi N, Sugai T, Masuda T, et al. Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol Rep 2012;28:867-873.
28. Simon D, Laloo B, Barillot M, Barnetche T, Blanchard C, Rooryck C, et al. A mutation in the 30-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia. Hum Mol Genet 2010;19:2015-2027.
29. Huang S, Wang S, Bian C, Yang Z, Zhou H, Zeng Y, et al. Upregulation of miR- 22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem Cells Dev 2012;21:2531-2540.
30. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
31. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716-23724.
32. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334:1351-1358.
33. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001;153:1023-1034.
34. Horiguchi N, Takayama H, Toyoda M, Otsuka T, Fukusato T, Merlino G, et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 2002;21:1791-1799.
35. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NFkappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
36. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009;16:295-308.
37. Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, et al. Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012;122:586-599.